The concern of generic rivalry has consistently loomed above copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the future of similar medicinal investments. While initial periods saw substantial gains, the intellectual property lapse has opened the door for discounted alternatives, likely reducing profitability and presenting